SEAGEN
Seattle Genetics is a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in the pivotal trial for patients with relapsed or refractory Hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a... humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1997 and is headquartered in Bothell, Washington.
SEAGEN
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
1998-01-01
Address:
Bothell, Washington, United States
Country:
United States
Website Url:
http://www.seagen.com
Total Employee:
1001+
Status:
Active
Contact:
6192707227
Email Addresses:
[email protected]
Total Funding:
1.74 B USD
Technology used in webpage:
Content Delivery Network IPv6 Microsoft Azure DNS ReCAPTCHA V2 Microsoft ASP.NET Ajax Google Cloud Global Multi-Region Google Analytics IP Anonymization Google Cloud CDN Level 3 Communications
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2018-01-31 | Cascadian Therapeutics | Cascadian Therapeutics acquired by Seagen | 614 M USD |
Investors List
Merck
Merck investment in Post-IPO Equity - Seagen
Takeda
Takeda investment in Post-IPO Equity - Seagen
New Enterprise Associates
New Enterprise Associates investment in Post-IPO Equity - Seagen
Sofinnova Investments
Sofinnova Investments investment in Venture Round - Seagen
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2015-06-11 | Cogent Biosciences | Seagen investment in Series B - Cogent Biosciences | 65 M USD |
Key Employee Changes
| Date | New article |
|---|---|
| 2022-02-01 | Seagen Appoints Lee Heeson as Executive Vice President, Commercial International |
Official Site Inspections
http://www.seagen.com Semrush global rank: 746.98 K Semrush visits lastest month: 54.08 K
- Host name: 172.64.153.181
- IP address: 172.64.153.181
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Seagen"
Seagen - Pfizer
With the addition of Seagen, a world-leader in antibody-drug conjugates (ADCs), we will be at the forefront of cancer care. Together, we will bring new hope to patients everywhere. ... as we …See details»
Pfizer Completes Acquisition of Seagen
Dec 14, 2023 Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion. ... as we bring …See details»
Pfizer Receives All Required Regulatory Approvals to Complete the ...
Dec 12, 2023 Expects to close Seagen acquisition on December 14, 2023 Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and …See details»
Seagen - Wikipedia
Seagen Inc. (formerly Seattle Genetics, Inc.) is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington (a suburb of Seattle), is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. An…See details»
Seagen - Dedicated to revolutionizing cancer care - Pfizer
For 25 years, Seagen has advanced the development of targeted cancer therapeutics with ADC technology at our core, a drug class we have pioneered since 1998. Our rich history of …See details»
Pfizer Completes Acquisition of Seagen - Business Wire
Dec 14, 2023 This press release contains forward-looking information about, among other topics, Pfizer’s acquisition of Seagen, Seagen’s ADC technology, Pfizer’s Oncology portfolio …See details»
Pfizer expects to close Seagen deal on Thursday, will create a new ...
Dec 12, 2023 Pfizer is also planning changes to its commercial organization to better incorporate Seagen and improve focus and speed of execution. The company will create an end-to-end …See details»
Pfizer gets OK for $43-billion Seagen deal after …
Dec 12 (Reuters) - Pfizer , opens new tab said on Tuesday it expects to close its $43 billion deal to buy cancer drugmaker Seagen , opens new tab later this week and plans to create a new oncology ...See details»
Pfizer Invests $43 Billion to Battle Cancer
Pfizer to acquire Seagen for $229 per Seagen share in cash, for a total enterprise value of approximately $43 billion Proposed combination enhances Pfizer’s position as a leading …See details»
Pfizer Completes Acquisition of Seagen - Yahoo Finance
NEW YORK, December 14, 2023--Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Seagen Inc. (NASDAQ: SGEN), a global biotechnology company that discovers ...See details»
Seagen - Crunchbase Company Profile & Funding
Organization. Seagen . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Seagen closed its last funding round on Sep 14, 2020 from a Post-IPO Equity round. Who are …See details»
Information for Healthcare Professionals – Seagen - Pfizer
Seagen is a global biotechnology company dedicated to revolutionizing cancer care. We’re developing transformative therapies that make a meaningful difference. In it to advance cancer …See details»
Our Mission, Vision, and Values – Seagen
Seagen is now part of Pfizer! This page will no longer be updated, but you can visit Pfizer.com for more information on this change, or visit the "About" page on Pfizer.com Who we are. Seagen …See details»
Pfizer buys Seagen for $43B, boosts access to cancer drugs
Mar 13, 2023 Seagen also has a deal with Pfizer’s Array BioPharma to develop, make and sell the breast and colorectal cancer treatment Tukysa. It brought in $353 million in sales for …See details»
Pfizer Receives All Required Regulatory Approvals to Complete the ...
Dec 12, 2023 During the call Pfizer will discuss the Seagen acquisition, new commercial organization, and provide full-year 2024 financial guidance. To view and listen to the webcast, …See details»
Pfizer to buy oncology-focused biotech Seagen for $43bn
Mar 13, 2023 In 2023, Seagen expects revenue of about $2.2bn, a 12 per cent rise year on year. Pfizer believes that in 2030 Seagen could contribute more than $10bn in risk-adjusted revenues.See details»
Culture – Seagen - Pfizer
Regular happy hours and team events give Seagen employees a chance to unwind, celebrate milestones, and connect with colleagues. ... Our annual Science Day celebrates the …See details»
Pfizer Completes Acquisition of Seagen - Nasdaq
Dec 14, 2023 Pfizer Inc. today announced the successful completion of its acquisition of Seagen Inc., a global biotechnology company that discovers, develops and commercializes …See details»
Pfizer Completes Acquisition of Seagen
Dec 14, 2023 bring together the game-changing science and top talent of Seagen and Pfizer to form a leading Oncology organization,” said Chris Boshoff, Chief Oncology Officer and …See details»
Pfizer: One of the world's premier biopharmaceutical companies
Explore the world of Pfizer, a leading biopharmaceutical company with a 175-year legacy of breakthroughs in medicine and healthcare.See details»